In this study, we brought together our novel inhibitors of enolase, HEX, and POMHEX, as well as the glutaminase inhibitor CB-839, to investigate the redundancies between glycolysis and glutaminolysis for supporting tumor growth and viability in vitro and in vivo in ENO1-deleted gliomas. Here, HHEX is linked to glioma.